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ABSTRACT
The tumor suppressor p53 is a central regulator
of cell-cycle arrest and apoptosis by acting as a
transcription factor to regulate numerous genes.
We identified all human p53-regulated mRNAs by
microarray analyses and searched for protein-
coding genes which contain intronic miRNAs.
Among others, this analysis yielded the pantho-
thenate kinase 1 (PANK1) gene and its intronic
miRNA-107. We showed that miRNA-107 and
PANK1 are coregulated by p53 in different cell
systems. The PANK1 protein, which catalyzes
the rate-limiting step of coenzyme A biosynthesis,
is also upregulated by p53. We observed that
p53 directly activates PANK1 and miRNA-107
transcription through a binding site in the PANK1
promoter. Furthermore, p53 is recruited to the
PANK1 promoter after DNA damage. In order to
get more insight into miRNA-107 function we
investigated its potential target genes. Cell-cycle
regulators are significantly enriched among
predicted miRNA-107 targets. We found miRNA-
107-dependent regulation of two important regula-
tors of G1/S progression, CDK6 and the RB-related 2
gene RBL2 (p130). CDK6 and p130 proteins are
downregulated upon miRNA-107 expression. Our
results uncover a novel miRNA-dependent signaling
pathway which leads to downregulation of cell
cycle proteins in the absence of transcriptional
repression.
INTRODUCTION
miRNAs are short non-coding RNAs which have func-
tions in numerous cellular processes like differentiation,
cell survival and proliferation (1). Originally found in
Caenorhabditis elegans by their ability to interfere the
expression of the developmentally regulated lin-14 (2), it
later became apparent that miRNAs are expressed in a
wide variety of organisms including humans (3,4). They
act as adaptors in a large protein complex known as
RNA-induced silencing complex (RISC) (5) and direct
sequence-speciﬁc target-mRNA recognition through
imperfect base pairing to their untranslated regions (6,7).
miRNAs can act on mRNA stability by recruitment
of the CAF1-CCR4-NOT deadenylation complex
and the decapping enzymes DCP-1 and DCP-2 (8,9).
Furthermore, miRNAs can interfere with translation of
target mRNAs (9–12). Elucidating the contribution of
these mechanisms to the repression effect of a miRNA is
controversial. It has been shown that in mouse Krebs-2
ascites cell extracts inhibition of target mRNA translation
is initially induced and followed by degradation of the
mRNA (13). Therefore, translational repression and initi-
ation of RNA degradation may act synergistically on
target mRNAs. Many miRNAs were predicted to have
hundreds of target mRNAs in a cell due to the short
seed sequences which are needed to guide miRNA/
mRNA binding. Proteome screening studies after
overexpression of different miRNAs have indeed shown
that hundreds of proteins are efﬁciently repressed, albeit
to a modest degree (14,15). Importantly, it has been shown
that only a few target genes are sufﬁcient to mimic a
miRNA-dependent complex phenotype. As an example
miRNA-31 is predicted to target hundreds of genes and
is able to inhibit breast cancer cell metastasis (16). After
re-expression of only three target genes, the cancer cells
were able to form metastases again, showing that expres-
sion of only a small proportion of miRNA target genes
are sufﬁcient for a speciﬁc signaling pathway (17). This
and other reports showed that miRNAs are speciﬁcally
over- or underexpressed in certain tumor types (18–20).
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tional regulation of miRNA genes is important for
gaining more insight into the function of miRNAs in
tumorigenesis.
The transcription factor p53 is a well known tumor
suppressor which is able to bind to speciﬁc palindromic
sequences (21). p53 is able to regulate a plethora of target
genes which function mostly in cell cycle control and
apoptosis induction (22). Cell cycle arrest is achieved
through induction of important CDK inhibitors like
p21
CIP1/WAF1 (23) and through transcriptional repression
of central cell cycle genes like Cdc25C (24), Cdc25A (25),
Cks2 (26) or Cyclin B (27). In addition to ‘classical’ func-
tions, p53 also inﬂuences ‘non-classical’ pathways like
controlling metabolism (28). One example of p530s
impact on metabolism is the enhancement of mitochon-
drial electron transport by inducing the cytochrome c
regulator synthesis of cytochrome c oxidase 2 (SCO2)
gene (29). Furthermore, glycolysis is shut down by p53
through transcriptional induction of the TP53-induced
glycolysis and apoptosis regulator (TIGAR) gene (30)
and through repression of the isomerase phosphoglycerate
mutase (PGM) gene (31). The regulation of these genes
prevents the shift of energy metabolism to glycolysis
which is characteristic for nearly all cancers (32). The
p53 target gene guanidinoacetate methyltransferase
(GAMT) is a key downstream effector after nutrient
deprival. GAMT induces fatty acid oxidation after
glucose starvation which restores energy supply (33).
Recently, p53 has been shown independently by several
groups to regulate miRNA transcription (34–38).
The miRNA-34 family is transcriptionally upregulated
by p53 and assists in initiating apoptosis. Also
miRNA-192, -215 and -194 are induced by p53, which
are mostly involved in the regulation of cell cycle arrest
(39,40). Intronic miRNAs are processed by the RNase
Drosha during splicing (41) and are frequently
co-expressed with their host genes (42). However, there
is only limited data on details of this coregulation. Often
it has not been investigated whether miRNAs are
regulated through the same promoters or the same
transcription factors as their host genes. For some
systems such studies have been carried out, e.g. E2F1
was shown to regulate miRNA-449 together with its
host gene Cdc20B (43). The miRNA-25, -93, -106b
cluster, which is intronic to the MCM7 gene, was shown
to be repressed by p53. This repression is mediated by
inhibition of E2F1 activity, which also controls MCM7
expression (44).
We studied intronic miRNAs of host genes regulated by
the tumor suppressor p53. By DNA microarray analyses
we observed that the host gene of miRNA-107, the
panthothenate kinase 1 (PANK1) gene, is upregulated by
p53. The coregulation of PANK1 and its intronic
miRNA-107 were characterized. The PANK1 locus was
observed to be activated through a p53-binding site in
the PANK1 promoter. Finally, we identiﬁed CDK6 and
the RB-related protein p130 as targets of miRNA-107
which have important functions at the G1/S transition of
the cell cycle.
MATERIAL AND METHODS
Cell culture, transient transfections and FACS analyses
HCT116, SaOS-2, D53wt and D53mut cell lines were
cultured as described (27). Human colon carcinoma
HCT116 cells wild-type or with targeted deletions of p53
(HCT116 p53
 / ) were treated with doxorubicin at a ﬁnal
concentration of 200ng/ml and harvested after 24 and
48h. Treatments with Mdm2-inhibiting nutlin-3 were per-
formed at 5mM for 24, 48 and 72h. Derivatives of the
colorectal carcinoma cell line DLD-1 were kindly
provided by Bert Vogelstein (D53wt, D53mut) (45).
These DLD-1 cells harboring an inactive 241F p53
mutant are stably transfected with a
tetracycline-responsive p53 expression system. Inductions
of p53wt and of the DNA-binding-deﬁcient mutant
p53R175H (p53mut) were performed by removal of tetra-
cycline from the cell culture media for 6, 9 or 15h.
Transfection of PANK1 expression plasmids into
HCT116 cells were done with FuGENE 6 (Roche,
Mannheim, Germany) according to the manufacturer’s
instructions. Transfection of control siRNA (medium
GC content, Invitrogen, Karlsruhe, Germany) and
validated p53 siRNA (Invitrogen) into HCT116 cells
were done with Dharmafect-1 (Dharmacon, Chicago, IL,
USA) at a ﬁnal concentration of 50nM. Cells were treated
with doxorubicin (800ng/ml) 24h after transfection.
D53wt cells were transfected with synthetic pre-miRNA-
107 (Ambion, Austin, TX, USA) at a ﬁnal concentration
of 100 and 150nM, respectively, using the siPORT
TM
NeoFX
TM transfection agent (Ambion). Cy3-labeled
control pre-miRNA (Ambion) was transfected at 150nM
and cells were harvested after 48h. miRNA-107-targeting
antisense RNAs (AntagomiR-107, Ambion) were trans-
fected into D53wt cells at a ﬁnal concentration of
60nM. Cy3-labeled control AntagomiR at 60nM was
used as a control. Additionally, we controlled the experi-
ments by transfection of D53wt cells without RNA
(mock). For luciferase reporter assays, SaOS-2 cells were
seeded at 50000 cells per well into 24-well plates.
Cotransfections were carried out with FuGENE 6 as
described above. The 400-ng PANK1 promoter constructs
in pGL4.10 (Promega, Madison, MA, USA) were
co-transfected together with 25-ng promoterless Renilla
luciferase (pGL4.70, Promega) and 25-ng expression
plasmid (p53wt, p53R175H or pcDNA3.1HisBlacZ).
Luciferase activity was normalized to co-transfected
Renilla luciferase activity in order to compensate for
different transfection efﬁciencies. Dual Luciferase Assays
(Promega) were performed after 24h. All experiments
were done in triplicate and repeated independently
at least three times. For testing putative miRNA-
107-binding sites, co-transfections of pGL4.10 UTR
reporter constructs together with pre-miRNA-107 and
control-pre-miRNA with a ﬁnal concentration of
100nM were performed with Dharmafect Duo
(Dharmacon) as suggested by the manufacturer.
For FACS analyses, D53wt cells were trypsinized,
centrifuged and resuspended in PBS (1mM EDTA).
Cells were ﬁxed by addition of three volumes of absolute
ethanol and incubation at 4 C overnight. Prior to FACS
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(1mM EDTA, with RNase A) and incubated with
propidiumiodide at 10mg/ml (SIGMA-Aldrich,
Steinheim, Germany) for 5min. All measurements were
performed on a FACScan instrument (Becton Dickinson,
NJ, USA). Data analysis was done with WinMDI 2.9
software.
Cloning and site-directed mutagenesis
PANK1 - and PANK1 -isoform cDNAs were cloned
from D53wt cDNA generated with Superscript III
(Invitrogen). PCR was performed with High Fidelity
Polymerase (Fermentas, St Leon-Rot, Germany) as
suggested by the manufacturer and PCR fragments were
cloned into pcDNA3.1(+) (Invitrogen). The PANK1 -
isoform in pcDNA3.1( ) was generously provided by
Dr Jackowski (46). The PANK1 promoter was cloned
from human genomic DNA into pGL4.10. Shorter
constructs were generated by PCR and subsequently
cloned in pGL4.10. Site-directed mutagenesis was
performed by quick-change-PCR with mutated primer
pairs and Pfu Turbo polymerase (Stratagene). For inves-
tigation of putative miRNA-107 binding sites, UTR
fragments of the CDK6 and p130 genes were cloned into
the XbaI site of pGL4.10. All inserts were sequenced to
control successful cloning. All primers used are outlined in
Supplementary Table S5.
Microarray analyses, real-time RT–PCR and northern
analysis
Total RNA preparations were done with TRIzol as
suggested by the manufacturer. Total RNA from
D53wt cells (control or after 9h induction) were
labeled by using standard procedures (Affymetrix,
Santa Clara, CA, USA). The RNA was hybridized on
Affymetrix U133 Plus 2.0 GeneChips. Scanned images
were evaluated using the Expression Console Software
(Affymetrix). All probe sets with a detection P<0.01
were assumed as being signiﬁcantly expressed.
Microarray data was deposited at the Gene Expression
Omnibus database under accession ID GSE21105.
Real-time RT–PCRs for mRNA measurements were per-
formed as previously described with the QuantiTect
SYBR Green RT–PCR kit (QIAGEN, Hilden,
Germany) on a LightCycler 3 system (Roche,
Mannheim, Germany). All measurements were
normalized to expression of GAPDH mRNA employing
the Ct-method. All RT–PCR primers used are
described in the Supplementary Tables. Expression of
mature miRNA-107 was measured by using TaqMan
miRNA Assays (Applied Biosystems, Foster City, CA,
USA). Total RNA was used for reverse transcription
with the MicroRNA Reverse Transcription Kit
(Applied Biosystems) according to the standard
protocol of the supplier. PCR was done on cDNA with
speciﬁc miRNA primer/probe set and Universal PCR
Mastermix (Applied Biosystems). miRNA expression
was normalized to expression of snoRNA U48 or
snRNA U6B.
Northern analyses were performed essentially as
described (47). Brieﬂy, D53wt, D53mut or HCT116 total
RNA was enriched for poly A RNA by using the Oligotex
mRNA Mini Kit (QIAGEN). Two micrograms of poly A
RNA were separated on a 2% agarose gel containing 1%
formaldehyde. After transfer on northern-blot membranes
(Bio-Rad, Mu ¨ nchen, Germany) RNA was crosslinked by
UV exposure. Probes were generated by T7 in vitro tran-
scription of PANK1 cDNA sub-cloned in pSPT18 (Roche,
Mannheim, Germany) with 50mCi a-
32P-CTP. Signal de-
tection was carried out using a PhosphoImager system
(Fuji). GAPDH mRNA was detected on the same blot
as a loading control.
Western blot
For western-blot analyses protein was precipitated accord-
ing to the TRIzol standard protocol and dissolved in 8M
urea buffer (50mM phosphate, 200mM NaCl, pH 8.0).
Western blot was done essentially as described previously
(27,48). After SDS gel electrophoresis and transfer of
proteins to PVDF membranes, 5% milk powder dissolved
in TBS buffer containing 0.1% Tween-20 was used to
block unspeciﬁc binding. The following primary
antibodies were used: DO1 mouse anti-p53 (1:2500,
DO1, Calbiochem, Darmstadt, Germany), mouse anti-
PANK1 (1:1000, Abnova, Taipei, Taiwan), mouse
anti-CDK6 (1:500, B-10, SantaCruz Biotech., Santa
Cruz, CA, USA), rabbit anti-p130 (1:1000, C-20, Santa
Cruz Biotech.), mouse anti-b-actin (1:5000, SIGMA-
Aldrich) and rabbit-anti-GAPDH (1:5000,
SIGMA-Aldrich). Secondary antibodies were rabbit
anti-mouse (1:5000, Thermo Scientiﬁc, Waltham, MA,
USA) and mouse anti-rabbit (1:5000, Thermo Scientiﬁc).
Chromatin immunoprecipitation
HCT116 p53
+/+ cells were treated with doxorubicin for
24h or left untreated as a control. Cellular proteins were
ﬁxed in 1% formaldehyde for 10min. Chromatin
immunoprecipitations were essentially done as described
earlier (49–51). The monoclonal DO1 p53 antibody was
used for precipitation of p53 and a non-targeting mouse
antibody was used as a control for unspeciﬁc signals. We
also included controls in which precipitation was carried
out without antibody. For all precipitations Protein G
Dynabeads (Invitrogen) were used. qPCR was carried
out with the QuantiTect SYBR Green PCR kit
(QIAGEN) and all primers were checked for equal amp-
liﬁcation efﬁciency. All PCR results were normalized to
input controls. ChIP primers are listed in Supplementary
Tables.
Luciferase assays
Twenty-four hours after transfection, SaOS-2 cells were
harvested with Passive Lysis Buffer (Promega). Fireﬂy
and Renilla luciferase activity were measured with the
Dual Luciferase Assay system (Promega). Relative light
units were calculated by normalizing ﬁreﬂy luciferase
values with Renilla luciferase activities. All measurements
were performed in triplicate and repeated independently at
least three times. Regulation by p53 was calculated by
442 Nucleic Acids Research, 2011,Vol. 39,No. 2dividing the relative light units of the p53wt-transfected
wells by the p53mut (p53R175H)-transfected wells.
RESULTS
Identiﬁcation of p53-regulated transcripts with intronic
miRNAs
Intronic miRNAs have been shown to be frequently
co-expressed with their host genes (42). These miRNAs
could also have similar regulation patterns as their
protein-coding host genes. We were interested in ﬁnding
p53 target genes with intronic miRNAs. To this end, we
carried out DNA microarray analyses with RNA from
D53wt cells which carry an inducible system for wild-type
p53 in a functionally p53-negative cellular background.
Induction of transgenic p53 is detectable already 6h after
removal of tetracycline (Supplementary Figure S1A). Cell
cycle arrest and apoptosis induced by p53 was monitored
byFACS(SupplementaryFigureS1B).Inordertomeasure
early effects of p53, we hybridized RNA from cells which
were induced for 9h and from non-induced control cells on
DNA microarrays representing all human mRNAs. In this
initial experiment, we identiﬁed 1425 transcripts which
were detected signiﬁcantly (P-value cutoff <0.01) and
regulated more than 3-fold (Supplementary Table S1). By
comparison of these potential direct targets with the
chromosomal localization of all miRNAs in the human
genome [miRBase release 14 (52)], 23 candidate genes
were identiﬁed (Supplementary Table S2). Interestingly,
we observed downregulation of MCM7 harboring the
miRNA-25, -93, -106b cluster which was shown to be
regulated by p53 (44). The PANK1/miRNA-107 gene
locus was chosen for further studies since miRNA-107
had been reported to induce cell cycle arrest in G1 upon
overexpression (53).
Regulation of PANK1 and miRNA-107 after induction
of p53
miRNA-107 is encoded in intron 5 of the PANK1 gene.
PANK1 is transcribed into three different isoforms
(PANK1 ,   and  ). PANK1  is generated through an
alternative transcription start upstream of the PANK1 
and PANK1  transcription start site (46). PANK1  and
  only differ in exon 4 which is spliced out in the PANK1 
isoform. In order to verify the results of the microarray
experiment, regulation of all PANK1 isoforms in D53wt
cells was tested. Induced expression of wild-type p53 led to
a 4.5-fold increase of PANK1 mRNA (Figure 1A). As a
control, the DNA-binding-deﬁcient p53 mutant R175H
was induced in the same cell system (D53mut) yielding
no signiﬁcant changes in expression of PANK1. Then we
addressed the question whether p53 induces all isoforms
or has only an impact on speciﬁc ones. Poly A-enriched
RNA preparations of D53wt and D53mut cells before and
after induction of the transgene were analyzed by
northern-blot assays. The RNA probe directed against
all PANK1 isoforms detected transcripts of four different
lengths which show an increased expression after p53 in-
duction (Figure 1B). The estimated lengths of the RNA
molecules correspond well to the annotated PANK1
isoforms (PANK1 , 2525bp; PANK1 , 2702bp;
PANK1 , 3367bp). The upper band at  5kb does not
correspond to a known isoform of PANK1. As a negative
control, induction of p53 mutant protein does not change
the expression of any detected RNA (Figure 1B).
Expression of all PANK1 isoforms is expected to
concomitantly lead to an increase of precursor
miRNA-107 levels. Thus, we measured pri-miRNA-107
levels by real-time RT–PCR and detected an increase
after induction of wild-type p53 but not after induction
of p53 mutant protein (Figure 1C). Consistently, also the
mature miRNA-107 is differentially expressed after p53
induction (Figure 1D). These analyses indicate that p53
upregulates miRNA-107 in tandem with PANK1 mRNAs.
The regulation of the PANK1/miRNA-107 gene locus is
dependent on a functional p53 DNA-binding domain.
PANK1 protein is also upregulated by p53 (Figure 2).
Interestingly, PANK1 protein whose molecular weight
corresponds to the PANK1a isoform ( 64kDa)
appeared to be the only protein isoform induced by p53
0
1
2
3
4
5
6 control induced
PANK1 mRNA (all isoforms)
p53wt p53mut
R
e
l
a
t
i
v
e
 
R
N
A
 
e
x
p
r
e
s
s
i
o
n
p53wt
Induction
p53mut
-+
6
4
3
kbp
2
1.5
1
GAPDH
PANK1
probe
+ -
2
1.5
1
0
1
2
3
4 control induced
p53wt p53mut
Mature miRNA-107 Pri-miRNA-107
0
1
2
3
4
5 control induced
p53wt p53mut
R
e
l
a
t
i
v
e
 
R
N
A
 
e
x
p
r
e
s
s
i
o
n
R
e
l
a
t
i
v
e
 
R
N
A
 
e
x
p
r
e
s
s
i
o
n
A
CD
B
Figure 1. Regulation of PANK1 mRNA and miRNA-107 after induc-
tion of p53wt. D53wt or D53mut cells were induced for 9h and total
RNA was extracted. (A) PANK1 mRNA was measured by real-time
RT–PCR using primers which detect all PANK1 isoforms. GAPDH
expression was used for normalization. (B) Northern analyses of
PANK1 isoforms after induction of p53wt and p53mut. An in vitro
transcribed
32P-labeled RNA probe was employed for detection of
PANK1 isoforms in poly A-enriched RNA preparations. GAPDH
mRNA was detected on the same blots as a control for equal
loading. (C) Pri-miRNA-107 was measured by RT–PCR with primers
located in intron 5 of the PANK1 gene. Fold-changes in RNA expres-
sion relative to the non-induced cells are shown. (D) Real-time RT–
PCR analyses of mature miRNA-107 expression in D53 cells. The small
snoRNA U48 served as an endogenous control and was used for nor-
malization. All RT–PCR results show averages and standard deviations
of three independent experiments.
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In order to ascertain that the antibody employed recog-
nizes all isoforms, we transfected expression plasmids
coding for PANK1a, b and g into HCT116 cells.
Western analysis showed that all isoforms are detected
by this antibody (Supplementary Figure S2). Thus, p53
upregulates the PANK1a protein. The other isoforms
may be expressed and could also be regulated, but their
expression is below the detection limit.
Regulation of PANK1 and miRNA-107 is also observed
with endogenous p53 levels
In order to investigate the regulation of PANK1 and
miRNA-107 in another well-controlled cell system we
used HCT116 p53
+/+ and HCT116 p53
 /  knockout
cells. Induction of PANK1 and miRNA-107 was tested
after doxorubicin-induced DNA damage. This treatment
leadstostabilizationofp53expressedfromtheendogenous
alleles. PANK1 mRNA is upregulated in HCT116 p53
+/+
cellsafter48hofdoxorubicintreatment,butnotaftertreat-
ment of HCT116 p53
 /  cells (Figure 3A). Northern
analyses detected only one isoform which is upregulated
after DNA damage in these cells. The length of the RNA
corresponds to PANK1  (Figure 3B). Expression of
pri-miRNA-107 and mature miRNA-107 is upregulated
in HCT116 p53
+/+ after doxorubicin treatment, but
remains essentially unchanged in HCT116 p53
 /  cells
(Figure 3C and D). In order to test whether p53 stabiliza-
tion alone is sufﬁcient to induce miRNA-107 expression,
wetreatedHCT116cellswiththeMDM2inhibitornutlin-3
(54). Also after nutlin-3-induced p53 stabilization mature
miRNA-107 is upregulated in HCT116 p53
+/+ cells but not
in p53
 /  knockout cells (Figure 3E). Thus, p53 is able to
regulate mature miRNA-107 expression in the absence of
other stress signals like DNA damage.
The p53-dependent regulation of pri-miRNA-107
indicates a regulation on the transcriptional level.
However, it has been shown that p53 is able to induce
miRNA expression by enhancing Drosha/DGCR8-
complex-dependent pre-miRNA processing of speciﬁc
miRNAs (55). This seems not to be the case for
miRNA-107 because pri-miRNA-107 is upregulated in
D53wt and HCT116 p53
+/+ cells. In order to control for
non-speciﬁc effects caused by the doxorubicin treatment
protocol, pri-miRNA-145 and pri-miRNA-34 expression
were compared. It would be expected that pri-miRNA-145
levels remain unchanged after treatment because it is
controlled through pre-miRNA processing, and
pri-miRNA-34 was described to be upregulated by p53
on the transcriptional level. We observed the differential
expression with an upregulation of pri-miRNA-34 and
pri-miRNA-145 remaining essentially unchanged after
doxorubicin treatment, which is consistent with earlier ob-
servations (55) (Supplementary Figure S3).
PANK1 protein levels before and after doxorubicin
treatment of HCT116 cells were also tested. Consistent
with the mRNA levels only PANK1a appeared differen-
tially expressed (Figure 4). PANK1a increased after
48h of doxorubicin treatment in HCT116 p53
+/+ cells.
In p53
 /  knockout cells, PANK1a expression remained
almost constant, indicating that its regulation is dependent
on functional p53 (Figure 4). In another experimental
approach we transfected a p53-targeting siRNA into
HCT116 p53
+/+ cells and treated them with doxorubicin.
miRNA-107 induction in response to this treatment after
48h was clearly impaired compared to the controls when
p53 siRNA was transfected (Figure 5A). Western analyses
show that PANK1a protein was upregulated after 48h of
doxorubicin treatment in cells transfected with the control
siRNA (Figure 5B) but not after transfection with p53
siRNA. These observations conﬁrm the p53-dependent
regulation of the PANK1/miRNA-107 gene locus in an
isogenic cellular context. Control experiments show that
p53 expression was efﬁciently blocked by the p53 siRNA
and regulation of the known target gene p21
CIP1/WAF1 was
abrogated after knockdown of p53 (Figure 5B). Taken
together, these results show that expression of PANK1
and miRNA-107 is dependent on functional p53.
The PANK1/miRNA-107 gene locus is a direct target
of p53
Our results indicated that PANK1 and miRNA-107 are
regulated at the transcriptional level. Direct p53 targets
are also expected to be regulated when translation is
blocked. However, indirect target genes are expected to
depend on regulation of intermediate proteins by p53.
Inhibition of translation should alleviate regulation of
these target genes. As positive and negative controls, we
tested two p53 targets with or without treatment of
the cells with the translation inhibitor cycloheximide
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Figure 2. PANK1 protein regulation after induction of p53. Protein
extracts from D53wt and D53mut cells were used for western-blot
analyses. PANK1 was detected before and after induction of p53wt
and p53mut. As a control, the induction of the transgenes and the
expression of b-actin were detected on the same blot.
444 Nucleic Acids Research, 2011,Vol. 39,No. 2(Figure 6A). The direct transcriptional target gene
p21
CIP1/WAF1 is upregulated after induction of wild-type
p53 irrespective of functional translation. As an example
for a gene indirectly controlled by p53, Cyclin B2 was
tested. Cyclin B2 mRNA is downregulated in the control
experiment but is not signiﬁcantly changed when transla-
tion has been inhibited (Figure 6A). Interestingly, RNA
levels of PANK1 and mature miRNA-107 are induced
after p53 expression independent of functional translation
(Figure 6B). This supports the notion that the PANK1/
miRNA-107 gene locus is a direct target of p53.
Bioinformatic analyses of putative promoter regions in the
PANK1 gene
Promoter regions exhibit characteristic epigenetic modiﬁ-
cations like histone H3K4 trimethylation (H3K4me3), a
high sensitivity to DNase treatment and/or an accumula-
tion of CpG islands. We searched several data sets from
genome-wide screening experiments provided by the
UCSC Genome Browser (56–58) for hints regarding po-
tential promoters in the PANK1/miRNA-107 locus
(Figure 7). Interestingly, only the region surrounding the
transcriptional starts of PANK1 ,   and   exhibits clas-
sical promoter properties. H3K4me3 peaks at exon 1 of
PANK1  and DNase sensitivity shows two peaks corres-
ponding to the regions just upstream of the two different
transcriptional start sites. PANK1  exon 1 displays a
high-GC content with an annotated CpG island.
However, these data do not show whether the CpG
island is functional or not. Generally, transcribed
regions are associated with histone H3K36 trimethylation.
This is observed throughout the whole gene. Interestingly,
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Figure 3. PANK1 mRNA and miRNA-107 regulation in HCT116 cells after doxorubicin treatment. (A) HCT116 p53wt
+/+ and p53wt
 /  cells were
treated with doxorubicin and harvested at different time points. PANK1 mRNA was measured and normalized to GAPDH expression. (B) HCT116
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32P-labeled RNA probes targeted against all three isoforms were used for hybrid-
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Nucleic AcidsResearch, 2011, Vol.39,No. 2 445there are two conserved p53-binding sites overlapping
with the ﬁrst exon of PANK1  (Figure 7, red box).
Chromatin immunoprecipitation combined with high-
throughput DNA sequencing in HCT116 and HeLa
cells indicates recruitment of RNA polymerase II to
the genomic region adjacent to the p53-binding sites
and the transcriptional start sites. There is no evidence
for intronic promoters in this gene. The bioinfor-
matic analyses support the hypothesis that miRNA-107
expression is controlled by the promoter of the PANK1
host gene.
The p53 is recruited to the basal PANK1 promoter after
DNA damage
In order to test if p53 can bind to the potential promoter
region of the PANK1/miRNA-107 locus, chromatin
immunoprecipitations were carried out before and after
induction of DNA damage in HCT116 cells. From the
precipitates several regions were PCR-ampliﬁed from the
PANK1 gene (Figure 8A). No differential p53 recruitment
in the region 2200-bp upstream of the PANK1  start
codon was measured (amplicon 1). Interestingly, p53 is
recruited speciﬁcally to the region near the PANK1 ,  
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446 Nucleic Acids Research, 2011,Vol. 39,No. 2and   transcriptional start sites after induction of DNA
damage as shown with detection of amplicons 2 and 3. We
measured no differential recruitment near miRNA-107,
neither to intron 3 nor intron 5 (Figure 8A). These
results indicate that p53 is recruited to the PANK1
promoter region and not to intronic DNA segments
close to miRNA-107.
The PANK1 promoter is inducible by p53
In order to test whether the PANK1 promoter is inducible
by p53, a 2021-bp fragment starting upstream of the
PANK1  and   start codon was cloned into a reporter
vector. Cotransfection experiments with p53wt and
p53R175H-expressing plasmids (p53mut) in p53-negative
SaOS-2 cells were carried out. The full-length 2-kbp
construct was induced 15.6-fold when coexpressed with
p53wt relative to the promoter activity obtained with
p53mut (Figure 8B). A truncated promoter (0.9kbp)
showed almost no induction after p53wt expression. We
also cloned 2026 bases upstream of the PANK1  start
codon (1578bp) which also encompasses a putative
p53-binding site 1874 bases upstream from the start
codon as predicted by p53FamTaG (59). However, this
promoter construct exhibited no activity and was not
inducible by p53 (Figure 8B). Furthermore, we tested
if a putative intronic promoter directly upstream of
miRNA-107 drives its expression. However, neither
activity nor inducibility of this construct indicated that
miRNA-107 is regulated by an additional intronic
promoter (data not shown), which further supports the
notion that miRNA-107 expression is driven by the
fragment starting upstream of the PANK1  and   start
codon.
Following these results, we searched for p53 binding
sites in the PANK1 promoter construct upstream of the
PANK1 ,   start codon. Two putative-binding sites were
predicted based on comparison between human, mouse
and rat sequences (Figure 7, red box). One of these two
sites was not functional (data not shown). However, after
mutation of the core regions of the other p53-binding
motif, inducibility of the promoter construct was almost
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Nucleic AcidsResearch, 2011, Vol.39,No. 2 447lost (Figure 8B). Even mutation of one of the two core
regions diminishes the ability of p53wt to induce the
promoter. Taken together, the results imply that the
PANK1/miRNA-107 locus is directly regulated by p53
and that this regulation is mediated through p53 recruit-
ment to the PANK1 promoter.
Bioinformatic prediction of miRNA-107 targets
After investigating the mechanism of PANK1/
miRNA-107 locus regulation, we focused on possible
miRNA-107 functions in the context of p53 signaling.
Different algorithms for in silico prediction of miRNA
target genes exist. One single algorithm mostly predicts
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448 Nucleic Acids Research, 2011,Vol. 39,No. 2hundreds of putative targets. In order to yield a low false
positive rate, we employed the three prediction algorithms
miRanda (60), PicTar (61) and Targetscan (62). We found
115 putative targets which were common to predictions by
the three algorithms (Supplementary Table S3). These
results were subjected to gene ontology analyses employ-
ing the FatiGO algorithm (63). We noticed 17 terms which
were signiﬁcantly enriched in the list of putative targets,
among them were the terms ‘cell cycle’, ‘cell division’ and
‘regulation of cell cycle’ (Supplementary Table S4).
Thirteen cell cycle genes were identiﬁed with these terms:
CDK6, PNN, NEDD9, KIF23, FGF2, LATS2, SUFU,
MTSS1, RASSF5, CDC37L1, NF1, MYB and YWHAH.
One of these is the cyclin-dependent kinase 6 (CDK6). The
protein product of the gene initiates G1/S progression
when bound by cyclin D.
Important G1/S cell cycle phase proteins are regulated by
miRNA-107 by interference with translation
CDK6 had already been implicated as a miRNA-107
target (53). Expression of the kinase was assessed only
after overexpressing miRNA-107, and it was left open
whether CDK6 is regulated solely at the protein level or
if CDK6 mRNA degradation is induced by miRNA-107.
In order to characterize the regulation of CDK6 by
miRNA-107, we transfected synthetic miRNA-precursors
into D53wt cells and analyzed protein expression. CDK6
protein expression appeared slightly lower after transfec-
tion of pre-miRNA-107 compared to the control-pre-
miRNA (Figure 9A, left panel) which is in agreement
with earlier reports (53). The inverse experiment
knocking down endogenous miRNA-107 with speciﬁc
AntagomiR-107 yielded higher protein expression of
CDK6 compared to the controls (Figure 9A, right
panel). In order to ensure that changes in CDK6 protein
levels are not due to a shift in cell-cycle distribution, we
performed FACS analyses. Under the experimental con-
ditions employed, the cell cycle-distribution of D53wt cells
remained constant (Supplementary Figure S4). CDK6
mRNA was essentially unchanged under all experimental
conditions (Figure 9B). Therefore, it is likely that CDK6
is regulated by interference with translation and not by
initiation of RNA degradation.
Furthermore, we tested whether other proteins
which are important for progression from G1 to S phase
are also under control of miRNA-107 like the RB-related
pocket protein p130 (RBL2). Analysis of protein expres-
sion showed that p130 levels decrease after overexpression
of miRNA-107. In contrast, AntagomiR-directed
knockdown of endogenous miRNA-107 leads to an
elevated p130 expression compared to the control
(Figure 9C). Expression of p130 mRNA increased
slightly after miRNA-107 overexpression and knockdown
of miRNA-107 (Figure 9D). Thus, its expression is not
correlated with protein expression. Control RT–PCR ex-
periments showed that overexpression and knock-down of
miRNA-107 was successful (Figure 9E and F). In order to
investigate whether CDK6 and p130 are directly targeted
by miRNA-107 we cloned putative miRNA-107-binding
sites into the 30-UTR of the luciferase gene in the pGL4.10
reporter vector. We used the RNAhybrid algorithm (64)
to predict miRNA-107-binding sites in the p130 30-UTR.
One region was identiﬁed which could serve as such a
binding site and we cloned it into the 30-UTR of a
luciferase gene. From the CDK6 30-UTR one conserved
element was chosen which had been investigated earlier
(55). Overexpression of miRNA-107 led to a decrease of
CDK6 reporter activity (Supplementary Figure S5). This
supports the notion that CDK6 is directly controlled by
miRNA-107. The p130 UTR construct, however, only
slightly changed reporter activity after overexpression of
miRNA-107. Knockdown of miRNA-107 had no effect on
either reporter constructs. In summary, the results indicate
that CDK6 and p130 protein levels are under control of
miRNA-107 but p130 may not be a direct target of this
miRNA.
DISCUSSION
The tumor suppressor p53 regulates transcription of
numerous genes including miRNA genes. We showed
that p53 is able to coregulate intronic miRNA-107 by
transcriptional induction of its host gene PANK1.
PANK1 mRNA and protein appear to be regulated in
different cell systems. In HCT116 cells we could show
that p53 stabilization even in the absence of stress
signals is sufﬁcient to induce miRNA-107. The PANK1/
miRNA-107 gene is a direct target of p53 and is transcrip-
tionally induced by speciﬁc recruitment of p53 to the
PANK1 promoter after induction of DNA damage. We
identiﬁed a conserved p53-binding site in the PANK1
promoter which overlaps with exon 1 of the PANK1 
isoform. An intronic promoter which drives miRNA-107
expression under normal conditions, explicitly in a regular
non-DNA damage situation, has been described very
recently (65). However, here we observed that p53 is
neither recruited to this genomic region after DNA
damage nor is this DNA segment able to induce expres-
sion in a reporter assay. Taken together, the collected data
is consistent with the idea that the p53-inducible promoter
is located in the genomic region upstream of the transcrip-
tion start site of the PANK1  and   isoforms.
While this article was in preparation, a report was pub-
lished which identiﬁed a p53-binding site 1811-bp away
from the transcriptional start site of PANK1  as being
responsible for p53-dependent induction of the PANK1
gene (66). This binding site is predicted by the
p53FamTaG algorithm and is included in the 1578 con-
struct which was investigated here in reporter assays.
However, the region upstream of the PANK1  start
codon has no signiﬁcant promoter activity. Basal
promoter activity is generated by the 0.9-kbp upstream
of the PANK1 ,   start codon. Furthermore, in our
assays this binding site neither contributes to induction
of the PANK1 promoter activity nor is p53 recruited to
this genomic position after DNA damage. Our data
suggest that p53 regulates the PANK1 promoter through
binding to a conserved binding site downstream of the
PANK1  start codon.
Nucleic AcidsResearch, 2011, Vol.39,No. 2 449PANK1 protein is involved in coenzyme A biosynthesis
which is of great importance to the maintenance of meta-
bolic homeostasis (46,67). It catalyses the rate-limiting
step of coenzyme A biosynthesis. The interesting observa-
tion that the PANK1a protein is induced after DNA
damage in a p53-dependent manner raises the exciting
question of a possible inﬂuence of p53 on coenzyme A
levels in the cell. PANK1  transcription is also regulated
by PPARa which leads to higher PANK1 enzyme activity
(46). Thus, a p53-dependent induction of PANK1a could
lead to increased coenzyme A levels in the cell. Coenzyme
A is needed for a plethora of metabolic and anabolic
pathways. As an example, the tricarboxylic acid cycle
drives the acetyl-coenzyme A-dependent generation of
NADH which is oxidized in the mitochondrial electron
transport chain. An increased PANK1a level could
guarantee the supply with coenzyme A for this metabolic
pathway under stress conditions. The p53 target gene
guanidinoacetate methyltransferase (GAMT) initiates
fatty acid b-oxidation (33), a metabolic pathway leading
to fatty acid degradation by successive oxidation and
transfer of acetyl groups to coenzyme A. PANK1 induc-
tion by p53 could be important for the maintenance of this
alternative energy supply pathway. Interestingly, some
tumors have a lower coenzyme A level as the correspond-
ing normal tissue (68).
Finally, we identiﬁed two proteins regulated by
miRNA-107, CDK6 and the RB-related 2 gene RBL2
(p130). After knockdown of miRNA-107 CDK6 and
p130 protein levels slightly increase. Also a reduced ex-
pression of CDK6 and p130 on the protein level is
observed upon miRNA-107 overexpression. The small
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450 Nucleic Acids Research, 2011,Vol. 39,No. 2extend of protein repression has been observed for
numerous targets by proteome analyses. Quantiﬁcation
of protein expression by SILAC after miRNA over-
expression or miRNA knockdown often yields numerous
regulated targets. Only some of them were changed
>2-fold (14,15). This indicates that miRNAs usually
ﬁne-tune protein expression. miRNAs mediate their
effects through binding sites in the 30-UTR of target
mRNAs. We identiﬁed a binding site in the CDK6
30-UTR which downregulates reporter activity upon
overexpression of miRNA-107. A predicted miRNA-
107-binding site in the p130 UTR, however, did not
change reporter activity. This indicates that p130 may be
indirectly targeted by miRNA-107, through the regulation
of other proteins. We also performed knockdown of
miRNA-107 together with cotransfection of UTR
reporter constructs, but luciferase reporter activity did
not change compared to controls (data not shown). The
5-fold downregulation of endogenous miRNA-107 by the
AntagomiR employed appears not to be sufﬁcient to
induce a signiﬁcant increase in luciferase protein which
is transcribed from an exogenously introduced plasmid.
CDK6 and p130 exert important functions in the
progression from G1 to S phase. p53 mediates a very
fast cell cycle arrest. This function is mediated by
numerous target genes, for example by induction of
p21
CIP1/WAF1 (23) or repression of cyclin B (27) and
many other cell cycle genes. The regulation of
miRNA-107 and the resulting decrease in CDK6 and
p130 protein could therefore assist cell cycle arrest at the
G1/S transition. In fact, overexpression of miRNA-107
has been shown to induce G1/S cell cycle arrest in
human non-small cell lung cancer cell lines (53).
Additionally, the data presented here show another way
of p53-dependent repression of important cell-cycle regu-
lators which is not mediated by transcriptional effects but
by the interference of a regulated miRNA with transla-
tion. Although the effect of miRNA-107 on individual
proteins is rather low, the synergistic regulation of
several targets acting in the same pathway could lead to
cell cycle deregulation. It should be noted, however, that
also other p53-dependent regulatory pathways may exist
leading to altered expression of CDK6 and p130 proteins,
making it difﬁcult to determine miRNA-107-speciﬁc
contributions following p53 activation.
miRNA-107 was recently shown to inhibit tumor angio-
genesis through regulation of the target gene HIF1  (66).
Downregulation of HIF1b protein led to decreased VEGF
production which signiﬁcantly reduced angiogenesis in
a tumor xenograft mouse model. These results show
that miRNA-107 acts as a tumor suppressor. Together
with data described here, this hypothesis is further
supported since central cell-cycle proteins are repressed
by miRNA-107.
The data presented here provide a novel p53-dependent
pathway for cell cycle protein repression. It sheds light on
the complex regulation patterns which have evolved in the
human genome. As the transcriptome displays an amazing
complexity, the emerging underlying regulatory pathways
may be more interwoven than appreciated to date.
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